Tokyo, April 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057744) titled 'Effects of consumption of the test food on blood amino acid levels: a randomized, open-label, single-ingestion, crossover comparison study' on April 30.
Study Type:
Interventional
Study Design:
Basic Design - Cross-over
Randomization - Randomized
Blinding - Open -no one is blinded
Control - Active
Primary Sponsor:
Institute - PlasMEDi Inc.
Condition:
Condition - Healthy Japanese
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To verify the effects of consumption of the test food on blood amino acid levels
Basic objectives2 - Efficacy
Intervention:
Interventions/Control_1 -
Single ingestion
Test 1: High protein powder
Test 2: Commercially available milk (Meiji Oishii Gyunyu)
Test 1: Dissolve 20 g of high protein powder in 442 mL of water and consume it within 15 minutes after completing the pre-consumption measurement.
Test 2: Consume 442 mL within 15 minutes after completing the pre-consumption measurement.
*The intervention sequence is Test 1 to Test 2.
*The washout period is one week or more.
Interventions/Control_2 -
Single ingestion
Test 1: Commercially available milk (Meiji Oishii Gyunyu)
Test 2: High protein powder
Test 1: Consume 442 mL within 15 minutes after completing the pre-consumption measurement.
Test 2: Dissolve 20 g of high protein powder in 442 mL of water and consume it within 15 minutes after completing the pre-consumption measurement.
*The intervention sequence is Test 1 to Test 2.
*The washout period is one week or more.
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - 1. Japanese
2. Men or women
3. Individuals aged between 20 and 60
4. Healthy individuals
5. Individuals whose body mass index (BMI) is less than 30 kg/m2 at screening
Key exclusion criteria - 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
5. Individuals who are taking or using medications (including herbal medicines) or supplements
6. Individuals who are allergic to medicines or foods related to the test product
7. Individuals whose lifestyles are irregular due to working a late-night shift or others
8. Individuals who have food allergies or food intolerances, particularly lactose intolerance
9. Individuals who have developed abdominal pain or gastrointestinal symptoms due to consuming high-protein foods
10. Individuals who have or are undergoing medical treatment for diseases that influence digestion and absorption of nutrients
11. Individuals who are taking steroids, protease inhibitors, or antipsychotics
12. Individuals who are smokers
13. Individuals who have difficulty consuming the food in the prescribed administration
14. Individuals who are pregnant, lactating, or planning to become pregnant during this study
15. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
16. Individuals who are judged as ineligible to participate in this study by the physician
Target Size - 14
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2025 Year 04 Month 09 Day
Date of IRB - 2025 Year 04 Month 09 Day
Anticipated trial start date - 2025 Year 04 Month 30 Day
Last follow-up date - 2025 Year 06 Month 25 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065983
Disclaimer: Curated by HT Syndication.